PRA Health Sciences Inc (PRAH) : Hood River Capital Management scooped up 184,235 additional shares in PRA Health Sciences Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 356,127 shares of PRA Health Sciences Inc which is valued at $16,289,249.PRA Health Sciences Inc makes up approximately 2.25% of Hood River Capital Management’s portfolio.
Other Hedge Funds, Including , Rhumbline Advisers boosted its stake in PRAH in the latest quarter, The investment management firm added 260 additional shares and now holds a total of 20,986 shares of PRA Health Sciences Inc which is valued at $959,900.Ifp Advisors Inc reduced its stake in PRAH by selling 1 shares or 3.13% in the most recent quarter. The Hedge Fund company now holds 31 shares of PRAH which is valued at $1,418. Strs Ohio sold out all of its stake in PRAH during the most recent quarter. The investment firm sold 18,200 shares of PRAH which is valued $901,264.
PRA Health Sciences Inc closed down -0.08 points or -0.17% at $46.5 with 4,15,526 shares getting traded on Tuesday. Post opening the session at $46.49, the shares hit an intraday low of $45.77 and an intraday high of $46.89 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, PRA Health Sciences Inc reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.53. The company had revenue of $372.30 million for the quarter, compared to analysts expectations of $372.06 million. The company’s revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on PRA Health Sciences Inc. PRA Health Sciences Inc was Upgraded by Citigroup to ” Buy” on May 4, 2016. PRA Health Sciences Inc was Upgraded by Sun Trust Rbsn Humphrey to ” Buy” on Mar 28, 2016.
PRA Health Sciences Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development including oncology central nervous system inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services which includes Phase IIb through III product registration trials and Phase IV trials inclusive of post-marketing commitments and registries; Strategic Solutions which provides Embedded Solutions and functional outsourcing services and Early Development Services which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.